Therapies to Preserve β-Cell Function in Type 1 Diabetes

Area of Science:

• Immunology
• Endocrinology
• Regenerative Medicine

Background:

• Type 1 diabetes mellitus (T1DM) poses significant health risks, including severe complications and mortality, despite advancements.
• Current single-drug therapies lack sufficient efficacy for T1DM management.
• The heterogeneous nature of T1DM necessitates personalized treatment strategies.

Purpose of the Study:

• To explore novel therapeutic approaches for T1DM beyond conventional treatments.
• To investigate the potential of combination therapies in halting T1DM progression.
• To identify strategies for preserving or enhancing beta-cell function and regeneration.

Main Methods:

• Review of existing and emerging T1DM treatment modalities.
• Analysis of combination therapy strategies involving immunosuppressants (anti-CD3, anti-CD20), fusion proteins (etanercept, abatacept), beta-cell protective agents, autoantigen therapy (GAD, proinsulin), and regenerative agents (GLP-1).

Main Results:

• Combination therapies demonstrate encouraging efficacy with mild adverse events.
• Specific combinations may halt the autoimmune destructive process in T1DM.
• Agents promoting beta-cell regeneration offer potential for disease modification.

Conclusions:

• Personalized combination therapies are crucial for managing T1DM subgroups.
• Combining immunosuppression with beta-cell regeneration and protection may lead to milder T1DM.
• These approaches hold promise for improving T1DM outcomes and potentially achieving a cure.